<DOC>
	<DOCNO>NCT01214291</DOCNO>
	<brief_summary>The purpose study determine whether Toremifene Citrate effective reducing risk bone fracture men prostate cancer Androgen Deprivation Therapy .</brief_summary>
	<brief_title>Efficacy Safety Study Toremifene Citrate Reduction Risk New Bone Fracture Occurrences Men With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>give voluntary sign informed consent histologically documented prostate cancer ADT treatment 6 month prior randomization intermittent LHRHa preceeding 12 month expect continue LHRHa therapy uninterrupted next 12 month total testosterone level less 50 ng/dL Have BMD lumbar spine femoral neck BMD thresholds Zubrod performance status &lt; equal 1 subject weight &lt; 300 lb ( &lt; 136 kg ) agree complete daily diary medication intake agree take exclude medication throughout trial agree use effective method contraception adequate bone marrow , liver renal function Currently previously expose within past 5 year intravenous bisphosphonates , strontium ranelate Denosumab 3 year oral bisphosphonates within last 45 day PTH PTH derivative , anabolic steroid testosterone , SERMs , calcitonin , calcitriol oral gluccorticoids disease condition would preclude accurate evaluation radiograph thoracic lumbar spine &lt; 8 evaluable vertebra BMD T score &lt; 4 lumbar spine total hip femoral neck history carcinoma within last 5 year Serum PSA &gt; 5ng/mL baseline ADT Paget 's disease , Cushing 's disease , chronic hepatitis cirrhosis rheumatoid arthritis active uncontrolled systemic viral , bacterial fungal infection clinically significant concurrent illness psychological , familial , sociological , geograhical condition would permit adequate followup compliance receive treatment investigational agent within 30 day take finasteride , dutasteride , danazol testosterone like substance take herbal medicine dietary supplement history thromboembolic disease include DVT pulmonary embolus QTcF &gt; equal 450 msec congenital acquire QTc prolongation HIV calcicum urolithiasis prohibiting use vitamin D</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>fracture</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>androgen deprivation therapy</keyword>
</DOC>